Business
Levicept Announces the Appointment of James Sandy as Chief Development Officer
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for OsteoarthritisSANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO). James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and d
About this update from Astrazeneca Plc
[{"type":"image","alt":"Levicept","displaySize":"","headline":null,"caption":"Levicept","className":"","disableSlideshowImg":false,"size":{"original":{"width":188,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/9f8a01fd15d573af01a6da631be642c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8xBz5fYdD.ywPf18ntIR0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9f8a01fd15d573af01a6da631be642c8","width":188,"height":57}},"lazy":false},{"type":"text","content":"Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis","length":90,"tagName":"p"},{"type":"text","content":"SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the appointment of James Sandy as Chief Development Officer (CDO).","length":271,"tagName":"p"},{"type":"text","content":"James brings over 30 years’ experience in the pharmaceutical and biotechnology industries covering a wide range of therapeutic areas and development phases I to IV. Most recently he was CDO at F-star Therapeutics where he was responsible for setting the strategy and overseeing the delivery, execution and management of multiple concurrent oncology clinical trials and broader development strategy. Prior to F-star, he held CDO roles at Ellipses Pharma, Immunocore and Creabilis Pharmaceuticals. His earlier career was at AstraZeneca and Pfizer in a variety of senior roles. Over his career, James has taken several drugs to MAA/BLA filing including Celebrex for the treatment of osteoarthritis (OA) pain.","length":705,"tagName":"p"},{"type":"text","content":"Previously a consultant to Levicept, as part of the executive leadership team, James will be responsible for supporting the CEO, previous F-star and Immunocore colleague, Eliot Forster, and CSO and co-founder Simon Westbrook in steering the development of LEVI-04 as well as assisting in a broad range of due diligence and funding activities.","length":342,"tagName":"p"},{"type":"text","content":"LEVI-04 [p75NTR-Fc] is the first in a new class of novel, safe and efficacious biological therapies being developed for the treatment of symptoms and underlying disease of OA. LEVI-04 inhibits NT-3, one of the neurotrophin family of ...